The Real Reason CGT Programs Struggle to Scale

Many CGT programs rely on fresh leukapheresis-derived starting material early on. The challenge is what happens when collections, logistics, and manufacturing no longer align as programs expand.

In cell and gene therapy (CGT), early decisions have a habit of sticking around longer than expected. Processes put in place to solve immediate problems often become the foundation everything else is built on, whether they were designed for that role or not. Starting material is a good example of this dynamic. The choice between working with fresh leukapheresis‑derived starting material or frozen, cryopreserved material is usually made early, when the focus is on feasibility and speed rather than durability.

Discover how:

• Early Workflow Decisions Create Long-Term Constraints
• Operational Variability Is a Major Source of Risk
• Cryopreservation Enables Flexibility, Standardization, and Scalability
• Integrated, Standardized Infrastructure Is Critical for Sustainable Growth

Download the info brief and learn how Cryoport Systems supports cryopreservation, biostorage, and logistics within a single vendor partnership and quality framework.